Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
5 September 2022 |
Main ID: |
NCT00819221 |
Date of registration:
|
07/01/2009 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
|
Scientific title:
|
A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors |
Date of first enrolment:
|
January 5, 2009 |
Target sample size:
|
44 |
Recruitment status: |
Terminated |
URL:
|
https://clinicaltrials.gov/show/NCT00819221 |
Study type:
|
Interventional |
Study design:
|
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
Phase 1
|
|
Countries of recruitment
|
Italy
|
Switzerland
| | | | | | |
Contacts
|
Name:
|
Jane Robertson, BSc, MBCHB, MD |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
AstraZeneca |
| | |
Key inclusion & exclusion criteria
|
Health Condition(s) or Problem(s) studied
|
Source(s) of Monetary Support
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|